Phase II trial of methotrexate-FAM (m-FAM) in adenocarcinoma of unknown primary

Joseph Treat; Steven C. Falchuk; Candide Tremblay; Marc Spielman; Paul V. Woolley; Jacques Rouesse; Dominic Sevin; Thierry Le Chevalier

doi:10.1016/0277-5379(89)90387-8

Phase II trial of methotrexate-FAM (m-FAM) in adenocarcinoma of unknown primary

Joseph Treat, Steven C. Falchuk, Candide Tremblay, Marc Spielman, Paul V. Woolley, Jacques Rouesse, Dominic Sevin, Thierry Le Chevalier

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Nineteen patients with adenocarcinoma of unknown primary were treated with the m-FAM regimen, consisting of methotrexate 50 mg/m² days 0, 28; 5-fluorouracil 600 mg/m² days 1, 8, 29, 36; Adriamycin® 30 mg/m² days 1, 29; and mitomycin-C 10 mg/m² day 1. All drugs were recycled every 56 days. No complete responses were seen. Seven patients (37%) achieved partial remission for a median duration of 11 months. An additional nine patients (47%) had stable disease for a median duration of 6 months. Median survival for responders was 16 months and was 10 months for those with stable disease. Toxicity was acceptable. This Phase II study attempted to evaluate the clinical impact of the pharmacological modulation of 5-fluorouracil with methotrexate, the goal being improvement of the results of FAM alone in adenocarcinoma of unknown primary. However, the addition of methotrexate, at least in the schedule employed in this study, did not appear superior to FAM.

Original language	English
Pages (from-to)	1053-1055
Number of pages	3
Journal	European Journal of Cancer and Clinical Oncology
Volume	25
Issue number	7
DOIs	https://doi.org/10.1016/0277-5379(89)90387-8
State	Published - Jul 1989

Keywords

Adenocarcinoma/drug therapy
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Doxorubicin/administration & dosage
Drug Evaluation
Female
Fluorouracil/administration & dosage
Humans
Lung Neoplasms/drug therapy
Male
Methotrexate/administration & dosage
Middle Aged
Mitomycin
Mitomycins/administration & dosage
Neoplasms, Unknown Primary

Access to Document

10.1016/0277-5379(89)90387-8

Cite this

@article{1709dd47ce3b44749d48bdfdc8bed958,

title = "Phase II trial of methotrexate-FAM (m-FAM) in adenocarcinoma of unknown primary",

abstract = "Nineteen patients with adenocarcinoma of unknown primary were treated with the m-FAM regimen, consisting of methotrexate 50 mg/m2 days 0, 28; 5-fluorouracil 600 mg/m2 days 1, 8, 29, 36; Adriamycin{\textregistered} 30 mg/m2 days 1, 29; and mitomycin-C 10 mg/m2 day 1. All drugs were recycled every 56 days. No complete responses were seen. Seven patients (37%) achieved partial remission for a median duration of 11 months. An additional nine patients (47%) had stable disease for a median duration of 6 months. Median survival for responders was 16 months and was 10 months for those with stable disease. Toxicity was acceptable. This Phase II study attempted to evaluate the clinical impact of the pharmacological modulation of 5-fluorouracil with methotrexate, the goal being improvement of the results of FAM alone in adenocarcinoma of unknown primary. However, the addition of methotrexate, at least in the schedule employed in this study, did not appear superior to FAM.",

keywords = "Adenocarcinoma/drug therapy, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Doxorubicin/administration & dosage, Drug Evaluation, Female, Fluorouracil/administration & dosage, Humans, Lung Neoplasms/drug therapy, Male, Methotrexate/administration & dosage, Middle Aged, Mitomycin, Mitomycins/administration & dosage, Neoplasms, Unknown Primary",

author = "Joseph Treat and Falchuk, {Steven C.} and Candide Tremblay and Marc Spielman and Woolley, {Paul V.} and Jacques Rouesse and Dominic Sevin and {Le Chevalier}, Thierry",

year = "1989",

month = jul,

doi = "10.1016/0277-5379(89)90387-8",

language = "English",

volume = "25",

pages = "1053--1055",

journal = "European Journal of Cancer and Clinical Oncology",

issn = "0277-5379",

publisher = "Pergamon Press",

number = "7",

}

TY - JOUR

T1 - Phase II trial of methotrexate-FAM (m-FAM) in adenocarcinoma of unknown primary

AU - Treat, Joseph

AU - Falchuk, Steven C.

AU - Tremblay, Candide

AU - Spielman, Marc

AU - Woolley, Paul V.

AU - Rouesse, Jacques

AU - Sevin, Dominic

AU - Le Chevalier, Thierry

PY - 1989/7

Y1 - 1989/7

N2 - Nineteen patients with adenocarcinoma of unknown primary were treated with the m-FAM regimen, consisting of methotrexate 50 mg/m2 days 0, 28; 5-fluorouracil 600 mg/m2 days 1, 8, 29, 36; Adriamycin® 30 mg/m2 days 1, 29; and mitomycin-C 10 mg/m2 day 1. All drugs were recycled every 56 days. No complete responses were seen. Seven patients (37%) achieved partial remission for a median duration of 11 months. An additional nine patients (47%) had stable disease for a median duration of 6 months. Median survival for responders was 16 months and was 10 months for those with stable disease. Toxicity was acceptable. This Phase II study attempted to evaluate the clinical impact of the pharmacological modulation of 5-fluorouracil with methotrexate, the goal being improvement of the results of FAM alone in adenocarcinoma of unknown primary. However, the addition of methotrexate, at least in the schedule employed in this study, did not appear superior to FAM.

AB - Nineteen patients with adenocarcinoma of unknown primary were treated with the m-FAM regimen, consisting of methotrexate 50 mg/m2 days 0, 28; 5-fluorouracil 600 mg/m2 days 1, 8, 29, 36; Adriamycin® 30 mg/m2 days 1, 29; and mitomycin-C 10 mg/m2 day 1. All drugs were recycled every 56 days. No complete responses were seen. Seven patients (37%) achieved partial remission for a median duration of 11 months. An additional nine patients (47%) had stable disease for a median duration of 6 months. Median survival for responders was 16 months and was 10 months for those with stable disease. Toxicity was acceptable. This Phase II study attempted to evaluate the clinical impact of the pharmacological modulation of 5-fluorouracil with methotrexate, the goal being improvement of the results of FAM alone in adenocarcinoma of unknown primary. However, the addition of methotrexate, at least in the schedule employed in this study, did not appear superior to FAM.

KW - Adenocarcinoma/drug therapy

KW - Adult

KW - Aged

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Doxorubicin/administration & dosage

KW - Drug Evaluation

KW - Female

KW - Fluorouracil/administration & dosage

KW - Humans

KW - Lung Neoplasms/drug therapy

KW - Male

KW - Methotrexate/administration & dosage

KW - Middle Aged

KW - Mitomycin

KW - Mitomycins/administration & dosage

KW - Neoplasms, Unknown Primary

UR - http://www.scopus.com/inward/record.url?scp=0024386391&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(89)90387-8

DO - 10.1016/0277-5379(89)90387-8

M3 - Article

C2 - 2759160

AN - SCOPUS:0024386391

SN - 0277-5379

VL - 25

SP - 1053

EP - 1055

JO - European Journal of Cancer and Clinical Oncology

JF - European Journal of Cancer and Clinical Oncology

IS - 7

ER -

Phase II trial of methotrexate-FAM (m-FAM) in adenocarcinoma of unknown primary

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this